Thrivent Financial for Lutherans
SCLN

Thrivent Financial for Lutherans’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Thrivent Financial for Lutherans’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-31,810
Closed -$356K – 2392
2017
Q3 		$356K Buy
31,810
+630
+2% +$6.95K ﹤0.01% 1726
2017
Q2 		$343K Buy
31,180
+2,320
+8% +$23.2K ﹤0.01% 1704
2017
Q1 		$283K Buy
28,860
+1,240
+4% +$12.4K ﹤0.01% 1762
2016
Q4 		$298K Buy
27,620
+2,060
+8% +$20.6K ﹤0.01% 1720
2016
Q3 		$262K Buy
25,560
+1,580
+7% +$17.2K ﹤0.01% 1756
2016
Q2 		$313K Buy
+23,980
New +$314K ﹤0.01% 1652

Thrivent Financial for Lutherans's SCLN Position: Q4 2017 in Review

Thrivent Financial for Lutherans sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 31,810 shares — an estimated $356K sold.

Thrivent Financial for Lutherans first reported a position in SCLN in Q2 2016 and held it in 6 quarters. The position peaked at $356K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

  • Thrivent Financial for Lutherans reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 31,810 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $356K.
  • Thrivent Financial for Lutherans first reported a position in Sciclone Pharmaceuticals Inc in Q2 2016 and held it in 6 quarters.
  • Thrivent Financial for Lutherans's Sciclone Pharmaceuticals Inc position peaked at $356K in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2017, filed 14 Feb 2018.